Effect of Ocrelizumab on B- and T-Cell Receptor Repertoire Diversity in Patients With Relapsing Multiple Sclerosis From the Randomized Phase III OPERA Trial

Discussion Our data illustrate that the diversity of CD4+/CD8+ T-cell receptor repertoires remained unaltered in OCR-treated patients with relapsing MS. Persistence of a highly diverse T-cell repertoire suggests that aspects of adaptive immunity remain intact despite extended anti-CD20 therapy. Trial Registration Information This is a substudy (BE29353) of the OPERA I (WA21092; NCT01247324) trial. Date of registration, November 23, 2010; first patient enrollment, August 31, 2011.

http://nn.neurology.org/cgi/content/short/10/4/e200118?rss=1

Source: Neurology Neuroimmunology and Neuroinflammation - April 24, 2023 Category: Neurology Authors: Laurent, S. A., Strauli, N. B., Eggers, E. L., Wu, H., Michel, B., Demuth, S., Palanichamy, A., Wilson, M. R., Sirota, M., Hernandez, R. D., Cree, B. A. C., Herman, A. E., von Büdingen, H.- C. Tags: Multiple sclerosis Research Article Source Type: research